Ann: Quarterly Activity Report & Appendix 4C, page-26

Not to mention the main value of the Striate deal was the upfront payment of roughly US $14m, which secured OCC's finances for furthering the rest of their pipeline AND upgrading their manufacturing facility without any dilution to the existing shareholders (something quite rare these days in small Aus biotech at that scale).

I had thought there was a chance the large upfront deal could mean the price per unit of Striate was at the lower end of people's expectations, but if the choice was between a larger upfront cash injection to fund our other major programs, or a marginally better price per unit of Striate, I think management made the better choice.

Also @Speckled keep in mind BH has purchased nearly 11,000 Striate units from us in the first 3 quarters of it being launched in the US, the last quarter accounting for half of that number alone. Kain also pointed out in a few posts above that BH is going to start selling Striate under a second brand name Perform, which should help boost market capture.

I don't think it will take long for our quarterly units sold to double again to 10,000/quarter (especially with additional overseas market entry happening this quarter). Even at the lower end of my estimates, if it's $50/unit that's $2 million in receipts per year once we get to 10,000 units/quarter.